186 related articles for article (PubMed ID: 32707907)
21. Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson's disease phenotypes.
Nuber S; Zhang X; McCaffery TD; Moors TE; Adom MA; Hahn WN; Martin D; Ericsson M; Tripathi A; Dettmer U; Svenningsson P; Selkoe DJ
NPJ Parkinsons Dis; 2024 Feb; 10(1):47. PubMed ID: 38424059
[TBL] [Abstract][Full Text] [Related]
22. Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein.
Sekigawa A; Fujita M; Sekiyama K; Takamatsu Y; Hatano T; Rockenstein E; La Spada AR; Masliah E; Hashimoto M
Mol Brain; 2012 Sep; 5():34. PubMed ID: 23013868
[TBL] [Abstract][Full Text] [Related]
23. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
24. Conformational templating of α-synuclein aggregates in neuronal-glial cultures.
Sacino AN; Thomas MA; Ceballos-Diaz C; Cruz PE; Rosario AM; Lewis J; Giasson BI; Golde TE
Mol Neurodegener; 2013 May; 8():17. PubMed ID: 23714769
[TBL] [Abstract][Full Text] [Related]
25. Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy.
Bodner CR; Maltsev AS; Dobson CM; Bax A
Biochemistry; 2010 Feb; 49(5):862-71. PubMed ID: 20041693
[TBL] [Abstract][Full Text] [Related]
26. Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells.
Assayag K; Yakunin E; Loeb V; Selkoe DJ; Sharon R
Am J Pathol; 2007 Dec; 171(6):2000-11. PubMed ID: 18055555
[TBL] [Abstract][Full Text] [Related]
27. Prion-like C-Terminal Domain of TDP-43 and α-Synuclein Interact Synergistically to Generate Neurotoxic Hybrid Fibrils.
Dhakal S; Wyant CE; George HE; Morgan SE; Rangachari V
J Mol Biol; 2021 May; 433(10):166953. PubMed ID: 33771571
[TBL] [Abstract][Full Text] [Related]
28. Library-Derived Peptide Aggregation Modulators of Parkinson's Disease Early-Onset α-Synuclein Variants.
Watt KJC; Meade RM; Williams RJ; Mason JM
ACS Chem Neurosci; 2022 Jun; 13(12):1790-1804. PubMed ID: 35613323
[TBL] [Abstract][Full Text] [Related]
29. Anti-aggregation Effects of Phenolic Compounds on α-synuclein.
Ono K; Tsuji M; Yamasaki TR; Pasinetti GM
Molecules; 2020 May; 25(10):. PubMed ID: 32456274
[TBL] [Abstract][Full Text] [Related]
30. The Parkinson-Associated Toxin Paraquat Shifts Physiological α-Synuclein Tetramers toward Monomers That Can Be Calpain-Truncated and Form Oligomers.
Nuber S; Selkoe DJ
Am J Pathol; 2023 May; 193(5):520-531. PubMed ID: 36773784
[TBL] [Abstract][Full Text] [Related]
31. Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson's Disease.
Tardiff DF; Lucas M; Wrona I; Chang B; Chung CY; Le Bourdonnec B; Rhodes KJ; Scannevin RH
Mol Neurobiol; 2022 Apr; 59(4):2171-2189. PubMed ID: 35060064
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor.
Nishizawa S; Sumi H; Satoh Y; Yamamoto Y; Kitazawa S; Honda K; Araki H; Kakoi K; Imamura K; Sasaki M; Miyahisa I; Satomi Y; Nishigaki R; Hirayama M; Aoyama K; Maezaki H; Hara T
Eur J Pharmacol; 2017 Jul; 807():21-31. PubMed ID: 28442322
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the in vivo induction and transmission of α-synuclein pathology by mutant α-synuclein fibril seeds in transgenic mice.
Rutherford NJ; Dhillon JS; Riffe CJ; Howard JK; Brooks M; Giasson BI
Hum Mol Genet; 2017 Dec; 26(24):4906-4915. PubMed ID: 29036344
[TBL] [Abstract][Full Text] [Related]
34. Anionic lipid vesicles have differential effects on the aggregation of early onset-associated α-synuclein missense mutants.
Watt KJC; Meade RM; Williams RJ; Mason JM
J Biol Chem; 2022 Dec; 298(12):102565. PubMed ID: 36208776
[TBL] [Abstract][Full Text] [Related]
35. Vesicle trafficking and lipid metabolism in synucleinopathy.
Fanning S; Selkoe D; Dettmer U
Acta Neuropathol; 2021 Apr; 141(4):491-510. PubMed ID: 32607605
[TBL] [Abstract][Full Text] [Related]
36. Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA.
Bétemps D; Verchère J; Brot S; Morignat E; Bousset L; Gaillard D; Lakhdar L; Melki R; Baron T
Acta Neuropathol Commun; 2014 Mar; 2():29. PubMed ID: 24624994
[TBL] [Abstract][Full Text] [Related]
37. Lipase regulation of cellular fatty acid homeostasis as a Parkinson's disease therapeutic strategy.
Fanning S; Cirka H; Thies JL; Jeong J; Niemi SM; Yoon J; Ho GPH; Pacheco JA; Dettmer U; Liu L; Clish CB; Hodgetts KJ; Hutchinson JN; Muratore CR; Caldwell GA; Caldwell KA; Selkoe D
NPJ Parkinsons Dis; 2022 Jun; 8(1):74. PubMed ID: 35680956
[TBL] [Abstract][Full Text] [Related]
38. α-Synuclein upregulates bim-mediated apoptosis by negatively regulating endogenous GCN5.
Azam S; Kim IS; Choi DK
Aging (Albany NY); 2022 Oct; 14(20):8292-8301. PubMed ID: 36309909
[TBL] [Abstract][Full Text] [Related]
39. E46K-like α-synuclein mutants increase lipid interactions and disrupt membrane selectivity.
Rovere M; Powers AE; Jiang H; Pitino JC; Fonseca-Ornelas L; Patel DS; Achille A; Langen R; Varkey J; Bartels T
J Biol Chem; 2019 Jun; 294(25):9799-9812. PubMed ID: 31048377
[TBL] [Abstract][Full Text] [Related]
40. Pre-fibrillar α-synuclein mutants cause Parkinson's disease-like non-motor symptoms in Drosophila.
Gajula Balija MB; Griesinger C; Herzig A; Zweckstetter M; Jäckle H
PLoS One; 2011; 6(9):e24701. PubMed ID: 21931820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
